TY  - GEN
AU  - Berger,Mark S
AU  - Leopold,Lance H
AU  - Dowell,James A
AU  - Korth-Bradley,Joan M
AU  - Sherman,Matthew L
TI  - Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse
SN  - 0167-6997
PY  - 2003///0421
KW  - Aged
KW  - Aminoglycosides
KW  - Anti-Bacterial Agents
KW  - adverse effects
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Clinical Trials as Topic
KW  - statistics & numerical data
KW  - Gemtuzumab
KW  - Humans
KW  - Leukemia, Myeloid, Acute
KW  - drug therapy
KW  - Licensure
KW  - Middle Aged
KW  - Secondary Prevention
KW  - Survival Rate
KW  - United States
KW  - United States Food and Drug Administration
KW  - legislation & jurisprudence
N1  - Publication Type: Journal Article; Review
UR  - https://doi.org/10.1023/a:1020658028082
ER  -